Test Price
2,800 AED✅ Home Collection Available
GJB2 Gene Deafness, Autosomal Recessive Type 1A Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO-Accredited NGS Processing covering full GJB2 gene.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily 8 AM – 11 PM.
- Clinical Guidance: Post-test telephonic consultation with a DHA-licensed Consultant Medical Genetics for result interpretation.
- Insurance Verification: Direct billing verification via WhatsApp +971 54 548 8731 with pre-authorization assistance.
Test Overview & Methodology
This comprehensive genetic test analyzes the entire coding region of the GJB2 gene to diagnose autosomal recessive deafness type 1A (DFNB1A), the most common cause of congenital hearing loss. Our Next Generation Sequencing (NGS) platform delivers a detection rate exceeding 99.5% for point mutations, indels, and copy-number variations, ensuring clinically actionable results.
| Feature | Our Test (NGS) | Closest Alternative |
|---|---|---|
| Methodology | Next Generation Sequencing (Full GJB2 Gene) | Multiplex Ligation‑dependent Probe Amplification (MLPA) / Single‑site PCR |
| Turnaround Time | 3–4 Weeks | 6–8 Weeks |
| Detection Rate | >99.5% for all point mutations, indels & CNVs | ~70–80% for common alleles only |
| Pre‑test Requirement | Genetic counselling & pedigree chart | Often limited to family history questionnaire |
* The NGS assay uses clinically validated bioinformatics aligned with current ACMG guidelines.
Physician Insight & Safety Protocols
“As a DHA-licensed Consultant Medical Genetics, I understand the profound impact of hereditary hearing loss on families. This GJB2 sequencing test offers a precise diagnosis, but results must always be interpreted in the context of a comprehensive clinical evaluation and pedigree analysis. A GJB2 variant does not exclusively determine the severity of hearing impairment. Please remember: do not discontinue any prescribed medication without consulting your physician.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
⚠️ Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Infants younger than 28 days, individuals with acute febrile illness, or patients who have received a blood transfusion within the last 4 weeks (risk of chimerism).
- ER Red Flags: Sudden severe hearing loss, vertigo, tinnitus accompanied by neurological deficits (slurred speech, facial droop, limb weakness) require immediate emergency evaluation.
Patient FAQ & Clinical Guidance
1. What is the GJB2 gene test and who needs it?
This test sequences the entire GJB2 gene to diagnose autosomal recessive deafness type 1A in newborns and adults with congenital hearing loss. It is recommended for families with a history of early‑onset deafness, couples planning pregnancy, and any individual exhibiting non‑syndromic sensorineural hearing loss. A genetic counselling session prior to testing helps interpret results within the family context.
2. How accurate is the NGS GJB2 test?
Our NGS platform achieves 99.9% diagnostic sensitivity by covering all coding exons, exon‑intron boundaries, and splice sites of GJB2, while also detecting copy‑number variations. The assay follows CAP/CLIA‑equivalent validation protocols and uses an average read depth greater than 500x to ensure no pathogenic variant is missed.
3. Does insurance cover the GJB2 test in UAE?
Direct billing verification is available via WhatsApp +971 54 548 8731 for most UAE insurers and DHA‑approved claims. We assist with pre‑authorization and provide a detailed cost‑breakdown (2800 AED) including the genetic counselling session. Coverage depends on your plan’s outpatient genetic testing benefits.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance Framework
All genetic testing and data handling procedures strictly adhere to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent and clinical safety protocols comply with Federal Decree-Law No. 4 of 2016 on Medical Liability. Our laboratory is DHA-licensed under Facility Number 1143 and undergoes periodic audits to maintain the highest standards of data security and clinical accuracy.
Clinical & Logistical Metadata
| Test Name | GJB2 Gene Deafness, Autosomal Recessive Type 1A Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily 8 AM – 11 PM) |
| Methodology Used | Next Generation Sequencing (NGS) – Full Gene Sequencing |
| ICD-10-CM Code | H90.3 (Sensorineural hearing loss, bilateral) |
| LOINC Code | 60674-4 (GJB2 gene full sequencing) |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians